Revolution Medicines D
D
RVMD
172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
If you had invested in Revolution Medicines ago, it would be worth $4,314 today, against $2,284 in SPY and $2,421 in QQQ.
Revolution Medicines key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Speculative (losing money)
- Day range
- 168.750 – 176.000
- 52-week range
- 61.500 – 224.310
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 37.26B USD
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- -9.15
- Volume
- 129,614
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 1.43
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 59.3/100Environment 56 · Social 62 · Governance 60
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mark A. Goldsmith
- Employees
- 883
- Website
- revmed.com
- IPO date
- 13 Feb 2020
Revolution Medicines earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
-1.22 USD
Revenue estimate
388.66M USD
Last quarter · Q3 FY2026
EPS-1.90Beat +19.1%Revenue197.60MBeat +672.4%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2027 | -0.49 | — | — | — | 596.25M | — | — | +201.75% | |
| Q2 FY2027 | -0.66 | — | — | — | 522.96M | — | — | +29,392.47% | |
| Q1 FY2027 | -0.85 | — | — | — | 443.74M | — | — | +18,198.46% | |
| Q4 FY2026 | -1.22 | — | — | — | 388.66M | — | — | +10,467.83% | |
| Q3 FY2026 | -2.35 | -1.90 | +19.15% | — | 25.58M | 197.60M | +672.44% | +11,615.41% | |
| Q2 FY2026 | -2.04 | -3.06 | -50.00% | — | 1.77M | — | — | -93.56% | |
| Q1 FY2026 | -1.84 | -2.29 | -24.46% | — | 2.43M | — | — | +102.08% | |
| Q4 FY2025 | -1.58 | -1.86 | -17.72% | — | 3.68M | — | — | +880.74% | |
| Q3 FY2025 | -1.42 | -1.61 | -13.38% | — | 1.69M | — | — | +387.26% | |
| Q2 FY2025 | -1.14 | -1.31 | -15.11% | — | 27.53M | — | — | +3,308.48% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 0.66 | — | — | — | 3.36B | — | — | +68.13% |
| FY2027 | -2.95 | — | — | — | 2.00B | — | — | +251.90% |
| FY2026 | -8.51 | — | — | — | 568.29M | — | — | +16,210.40% |
| FY2025 | -5.65 | -5.91 | -4.65% | — | 3.48M | — | — | +1,061.40% |
| FY2024 | -3.47 | -3.57 | -2.80% | — | 300.00K | — | — | -97.63% |
| FY2023 | -3.48 | -3.77 | -8.41% | — | 12.65M | — | — | -64.24% |
| FY2022 | -3.29 | -3.10 | +5.83% | — | 27.86M | 35.38M | +26.98% | +20.38% |
Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved
Revolution Medicines analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
253.47 USD
+47.13%
Analysts' 1-year price targets range from 179.00 to 320.00, with an average of 253.47.
Past year
1-year forecast
Strong sellStrong buy
Strong buy
18 ratings
| Buy | 17 | |
| Hold | 1 | |
| Sell | 0 |
12-month price target
| Highest target | 320.00 |
| Average target | 253.47 |
| Lowest target | 179.00 |
| Current price | 172.28 |
Revolution Medicines valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Forward P/E (FY2028)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 259.13
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 188.62
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 15.52
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
37.26B USD
+
Total debt
639.10M USD
−
Cash and short-term investments
3.65B USD
=
Enterprise value
34.25B USD
Valuation over time
Revolution Medicines against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2019 to FY2023: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: United Therapeutics, Incyte, Insmed, Alnylam Pharmaceuticals, Exelixis, and Neurocrine Biosciences, the US Biotechnology companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- Gross marginAt its median100.0%100.0%100.0%Against its peers: 1 of 7Peers' median 90.3%
- Operating marginLowest in 5 years-4,207.1%-4,207.1%-108.2%Against its peers: 7 of 7Peers' median 23.9%
- Net marginLowest in 5 years-3,768.3%-3,768.3%-95.2%Against its peers: 7 of 7Peers' median 20.9%
- Return on equityAbove its median-23.9%-36.3%-22.8%Against its peers: 6 of 7Peers' median 21.9%
- Free cash flow marginLowest in 5 years-3,094.1%-3,094.1%-104.3%Against its peers: 7 of 7Peers' median 26.3%
- Revenue growthLowest in 5 years-67.3%-67.3%148.2%Against its peers: 7 of 7Peers' median 21.3%
- Current ratioHighest in 5 years13.063.1113.06Against its peers: 1 of 7Peers' median 3.48
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Revolution Medicines growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 197.56M USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- -1.87B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 95.16%
- Operating margin
- -852.98%
- Net margin
- -946.82%
Revenue / Net income
Revenue Net income Net margin
Revolution Medicines revenue breakdown
By product
FY2022
100.0%Collaboration Revenue
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Collaboration Revenue | 35.38M | 100.0% | +20.4% |
Revolution Medicines financial health
- Cash and short-term investments
- 3.65B USD
- Total debt
- 639.10M USD
- Net cash
- 3.01B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- -1.44B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 8.36
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.27
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 4 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 11.23
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Revolution Medicines ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 102.39%
- Institutional holders
- 738 (+179)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 90.07%
Who owns the shares
Institutions 100.0% Others 0.0%
As of 30 Jun 2026
Shares free to trade
Free float 194.80M shares ·90.1% Closely held 21.49M shares ·9.9%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 1 | 2.31K | 4.62K |
| Q3 2026 | 0 | 79 | 252.37K | 633.08K |
| Q2 2026 | 0 | 34 | 299.42K | 504.71K |
| Q1 2026 | 0 | 31 | 725.36K | 382.37K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling PrepVerified against SEC filings
Title: Revolution Medicines
Sector: Healthcare
Industry: Biotechnology
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.